

AIM ImmunoTech (AMEX: AIM) sees bullish momentum after final patent approval in Japan for its Ampligen-based oncology treatments.
You can purchase shares of AIM ImmunoTech (AMEX:AIM) through any online brokerage.
Other companies in AIM ImmunoTech’s space includes: AbbVie Inc (NYSE:ABBV), Amgen Inc (NASDAQ:AMGN), Gilead Sciences Inc (NASDAQ:GILD), Vertex Pharmaceuticals Inc (NASDAQ:VRTX) and Regeneron Pharmaceuticals Inc (NASDAQ:REGN).
AIM ImmunoTech has a consensus price target of $4.00.
The stock price for AIM ImmunoTech (AMEX: AIM) is $0.1629 last updated October 26, 2026 at 12:24 PM EDT.
There are no upcoming dividends for AIM ImmunoTech.
AIM ImmunoTech does not have any upcoming earnings scheduled.
There is no upcoming split for AIM ImmunoTech.
AIM ImmunoTech is in the Health Care sector and Biotechnology industry. They are listed on the AMEX.
AIM ImmunoTech Inc is an immuno-pharma company focused on the research and development of therapeutics to treat multiple types of cancers, viral diseases, and immune-deficiency disorders, and to treat cancers for which there are currently inadequate...